with recommended essential medicines for common diseases in patients in Stockholm County Council (Healthcare Region), Sweden
ATLAS on substance use (2010) — Resources for the prevention and treatment of substance use disorders
Accessed: 14.03.2019
Harm reduction: evidence, impacts and challenges
-10-
Science Spotlight
February 14, 2018
World Drug Report 2017
-1-
Accessed: 14.03.2019
ATLAS on substance use (2010) — Resources for the prevention and treatment of substance use disorders
Accessed: 14.03.2019
ATLAS on substance use (2010)— Resources for the prevention and treatment of substance use disorder
Accessed: 14.03.2019
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
Doc. No.: INS/GDL/001-(Annexes)